Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154870890> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2154870890 endingPage "1126" @default.
- W2154870890 startingPage "1123" @default.
- W2154870890 abstract "In this issue of the European Respiratory Journal , Judson et al. [1] report the results of a large clinical trial involving two new potential therapies in sarcoidosis, a subcutaneous anti-tumour necrosis factor (TNF) agent, golimumab, and a novel anti-p40 (a component of both interleukin (IL)-12 and IL-23) agent, ustekinumab. The rationale for the use of anti-TNF agents in sarcoidosis is compelling, as TNF plays a central role in granuloma formation [2]. The use of anti-p40 (anti-IL-12/IL-23) also has a solid rationale based on the role of IL-12 in promoting T-helper (Th) type 1 immune responses and its upregulation in sarcoidosis. The role of the IL-23/Th17 pathways in sarcoidosis is less well established but the benefits of blocking IL-23 together with IL-12 is conceptually appealing in sarcoidosis [3].Given the clear rationale for testing these therapies in sarcoidosis, it is disappointing that neither therapy showed clinical benefit assessed by either primary or secondary end-points. These negative results follow a large trial of infliximab by many of these same investigators. In a randomised, placebo-controlled trial of infliximab in pulmonary sarcoidosis by Baughman et al. [4], there was a statistically significant 2.5% increase in forced vital capacity (FVC) % predicted with infliximab versus placebo and no significant differences for any of the major secondary end-points at 6 months. Although the authors suggest this was a robust response, healthcare payers (both corporations and governments) concluded that infliximab demonstrated only minimal improvement for patients with pulmonary sarcoidosis and cite this research as a reason to deny coverage of this therapy. Several studies find infliximab beneficial for progressive nonpulmonary manifestations of sarcoidosis [5, 6], but in aggregate, these studies have not led to regulatory approval for infliximab in sarcoidosis in either Europe …" @default.
- W2154870890 created "2016-06-24" @default.
- W2154870890 creator A5021382253 @default.
- W2154870890 date "2014-10-31" @default.
- W2154870890 modified "2023-10-16" @default.
- W2154870890 title "Negative clinical trials in sarcoidosis: failed therapies or flawed study design?" @default.
- W2154870890 cites W1987208829 @default.
- W2154870890 cites W1990608082 @default.
- W2154870890 cites W2040958678 @default.
- W2154870890 cites W2059731037 @default.
- W2154870890 cites W2068613242 @default.
- W2154870890 cites W2076158450 @default.
- W2154870890 cites W2088988429 @default.
- W2154870890 cites W2095236130 @default.
- W2154870890 cites W2111252491 @default.
- W2154870890 cites W2114911311 @default.
- W2154870890 cites W2119635899 @default.
- W2154870890 cites W2130860647 @default.
- W2154870890 cites W2131718547 @default.
- W2154870890 cites W2138676597 @default.
- W2154870890 cites W2138783361 @default.
- W2154870890 cites W2142665211 @default.
- W2154870890 cites W2313141792 @default.
- W2154870890 cites W4211032738 @default.
- W2154870890 doi "https://doi.org/10.1183/09031936.00156314" @default.
- W2154870890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25362122" @default.
- W2154870890 hasPublicationYear "2014" @default.
- W2154870890 type Work @default.
- W2154870890 sameAs 2154870890 @default.
- W2154870890 citedByCount "29" @default.
- W2154870890 countsByYear W21548708902015 @default.
- W2154870890 countsByYear W21548708902016 @default.
- W2154870890 countsByYear W21548708902017 @default.
- W2154870890 countsByYear W21548708902018 @default.
- W2154870890 countsByYear W21548708902019 @default.
- W2154870890 countsByYear W21548708902020 @default.
- W2154870890 countsByYear W21548708902021 @default.
- W2154870890 countsByYear W21548708902022 @default.
- W2154870890 countsByYear W21548708902023 @default.
- W2154870890 crossrefType "journal-article" @default.
- W2154870890 hasAuthorship W2154870890A5021382253 @default.
- W2154870890 hasBestOaLocation W21548708901 @default.
- W2154870890 hasConcept C126322002 @default.
- W2154870890 hasConcept C144024400 @default.
- W2154870890 hasConcept C148482608 @default.
- W2154870890 hasConcept C177713679 @default.
- W2154870890 hasConcept C2779318504 @default.
- W2154870890 hasConcept C2781301800 @default.
- W2154870890 hasConcept C36289849 @default.
- W2154870890 hasConcept C535046627 @default.
- W2154870890 hasConcept C71924100 @default.
- W2154870890 hasConceptScore W2154870890C126322002 @default.
- W2154870890 hasConceptScore W2154870890C144024400 @default.
- W2154870890 hasConceptScore W2154870890C148482608 @default.
- W2154870890 hasConceptScore W2154870890C177713679 @default.
- W2154870890 hasConceptScore W2154870890C2779318504 @default.
- W2154870890 hasConceptScore W2154870890C2781301800 @default.
- W2154870890 hasConceptScore W2154870890C36289849 @default.
- W2154870890 hasConceptScore W2154870890C535046627 @default.
- W2154870890 hasConceptScore W2154870890C71924100 @default.
- W2154870890 hasIssue "5" @default.
- W2154870890 hasLocation W21548708901 @default.
- W2154870890 hasLocation W21548708902 @default.
- W2154870890 hasOpenAccess W2154870890 @default.
- W2154870890 hasPrimaryLocation W21548708901 @default.
- W2154870890 hasRelatedWork W2032098698 @default.
- W2154870890 hasRelatedWork W2034194900 @default.
- W2154870890 hasRelatedWork W2071907783 @default.
- W2154870890 hasRelatedWork W2085862598 @default.
- W2154870890 hasRelatedWork W2095438549 @default.
- W2154870890 hasRelatedWork W2101946106 @default.
- W2154870890 hasRelatedWork W2136006960 @default.
- W2154870890 hasRelatedWork W2301351088 @default.
- W2154870890 hasRelatedWork W2409877361 @default.
- W2154870890 hasRelatedWork W4312373076 @default.
- W2154870890 hasVolume "44" @default.
- W2154870890 isParatext "false" @default.
- W2154870890 isRetracted "false" @default.
- W2154870890 magId "2154870890" @default.
- W2154870890 workType "article" @default.